Kirn DH - Search Results

1

Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer.

Kirn DH, Thorne SH. Kirn DH, et al. Nat Rev Cancer. 2009 Jan;9(1):64-71. doi: 10.1038/nrc2545. Nat Rev Cancer. 2009. PMID: 19104515 Review.

2

Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.

Kirn DH, Wang Y, Le Boeuf F, Bell J, Thorne SH. Kirn DH, et al. PLoS Med. 2007 Dec;4(12):e353. doi: 10.1371/journal.pmed.0040353. PLoS Med. 2007. PMID: 18162040 Free PMC article.

3

Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594.

Breitbach CJ, Thorne SH, Bell JC, Kirn DH. Breitbach CJ, et al. Among authors: kirn dh. Curr Pharm Biotechnol. 2012 Jul;13(9):1768-72. doi: 10.2174/138920112800958922. Curr Pharm Biotechnol. 2012. PMID: 21740365 Review.

4

Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.

Breitbach CJ, Arulanandam R, De Silva N, Thorne SH, Patt R, Daneshmand M, Moon A, Ilkow C, Burke J, Hwang TH, Heo J, Cho M, Chen H, Angarita FA, Addison C, McCart JA, Bell JC, Kirn DH. Breitbach CJ, et al. Among authors: kirn dh. Cancer Res. 2013 Feb 15;73(4):1265-75. doi: 10.1158/0008-5472.CAN-12-2687. Epub 2013 Feb 7. Cancer Res. 2013. PMID: 23393196 Clinical Trial.

5

Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963.

Thorne SH, Hwang TH, O'Gorman WE, Bartlett DL, Sei S, Kanji F, Brown C, Werier J, Cho JH, Lee DE, Wang Y, Bell J, Kirn DH. Thorne SH, et al. Among authors: kirn dh. J Clin Invest. 2007 Nov;117(11):3350-8. doi: 10.1172/JCI32727. J Clin Invest. 2007. PMID: 17965776 Free PMC article.

6

Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus.

Thorne SH, Kirn DH. Thorne SH, et al. Among authors: kirn dh. Expert Opin Biol Ther. 2004 Aug;4(8):1307-21. doi: 10.1517/14712598.4.8.1307. Expert Opin Biol Ther. 2004. PMID: 15268664 Review.

7

Synergistic interaction between oncolytic viruses augments tumor killing.

Le Boeuf F, Diallo JS, McCart JA, Thorne S, Falls T, Stanford M, Kanji F, Auer R, Brown CW, Lichty BD, Parato K, Atkins H, Kirn D, Bell JC. Le Boeuf F, et al. Mol Ther. 2010 May;18(5):888-95. doi: 10.1038/mt.2010.44. Epub 2010 Mar 16. Mol Ther. 2010. PMID: 20234341 Free PMC article.

8

Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF.

Kim JH, Oh JY, Park BH, Lee DE, Kim JS, Park HE, Roh MS, Je JE, Yoon JH, Thorne SH, Kirn D, Hwang TH. Kim JH, et al. Mol Ther. 2006 Sep;14(3):361-70. doi: 10.1016/j.ymthe.2006.05.008. Mol Ther. 2006. PMID: 16905462 Free article.

9

Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1.

Huang B, Sikorski R, Kirn DH, Thorne SH. Huang B, et al. Among authors: kirn dh. Gene Ther. 2011 Feb;18(2):164-72. doi: 10.1038/gt.2010.121. Epub 2010 Aug 26. Gene Ther. 2011. PMID: 20739958

10

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.

Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, Nieva J, Hwang TH, Moon A, Patt R, Pelusio A, Le Boeuf F, Burns J, Evgin L, De Silva N, Cvancic S, Robertson T, Je JE, Lee YS, Parato K, Diallo JS, Fenster A, Daneshmand M, Bell JC, Kirn DH. Breitbach CJ, et al. Among authors: kirn dh. Nature. 2011 Aug 31;477(7362):99-102. doi: 10.1038/nature10358. Nature. 2011. PMID: 21886163 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

135 results

Search Page